Cargando…

A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole

BACKGROUND: Aromatase (CYP19A1) regulates estrogen biosynthesis. Polymorphisms in CYP19A1 have been related to the pathogenesis of breast cancer (BC). Inhibition of aromatase with letrozole constitutes the best option for treating estrogen-dependent BC in postmenopausal women. We evaluate a series o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Garcia-Casado, Zaida, Guerrero-Zotano, Angel, Llombart-Cussac, Antonio, Calatrava, Ana, Fernandez-Serra, Antonio, Ruiz-Simon, Amparo, Gavila, Joaquin, Climent, Miguel A, Almenar, Sergio, Cervera-Deval, Jose, Campos, Josefina, Albaladejo, Carlos Vazquez, Llombart-Bosch, Antonio, Guillem, Vicente, Lopez-Guerrero, Jose A
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2830181/ https://www.ncbi.nlm.nih.gov/pubmed/20144226 http://dx.doi.org/10.1186/1471-2407-10-36

Ejemplares similares

Letrozole efficacy is related to human aromatase CYP19 single nucleotide polymorphisms (SNPs) in metastatic breast cancer
por: Colomer, R, et al.
Publicado: (2005)

Breast cancer in pregnancy: an institutional experience
por: Blanquisett, Abraham Hernández, et al.
Publicado: (2015)

The role of CDK4/6 inhibitors in early breast cancer
por: Gil-Gil, Miguel, et al.
Publicado: (2021)

Inclusion of non-inferiority analysis in superiority-based clinical trials with single-arm, two-stage Simon's design
por: Sampayo-Cordero, Miguel, et al.
Publicado: (2020)

Aromatase and Dual Aromatase-Steroid Sulfatase Inhibitors from the Letrozole and Vorozole Templates
por: Wood, Paul M, et al.
Publicado: (2011)

High-risk gastrointestinal stromal tumour (GIST) and synovial sarcoma display similar angiogenic profiles: a nude mice xenograft study
por: Giner, Francisco, et al.
Publicado: (2017)

A de novo complete BRCA1 gene deletion identified in a Spanish woman with early bilateral breast cancer
por: Garcia-Casado, Zaida, et al.
Publicado: (2011)

Lymphopenia in hospitalized patients and its relationship with severity of illness and mortality
por: Andreu-Ballester, Juan Carlos, et al.
Publicado: (2021)

Surrogate endpoints for early-stage breast cancer: a review of the state of the art, controversies, and future prospects
por: Gion, María, et al.
Publicado: (2021)

Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial
por: Di Cosimo, Serena, et al.
Publicado: (2022)

A New Paradigm in the Relationship between Gut Microbiota and Breast Cancer: β-glucuronidase Enzyme Identified as Potential Therapeutic Target
por: Fernández-Murga, M. Leonor, et al.
Publicado: (2023)

Immune checkpoint inhibitors: a physiology-driven approach to the treatment of coronavirus disease 2019
por: Di Cosimo, Serena, et al.
Publicado: (2020)

Tissue microarrays: applications in study of p16 and p53 alterations in Ewing's cell lines
por: Noguera, Rosa, et al.
Publicado: (2008)

Survival impact of primary tumor resection in de novo metastatic breast cancer patients (GEICAM/El Alamo Registry)
por: Lopez-Tarruella, Sara, et al.
Publicado: (2019)

Incorporating clinicopathological and molecular risk prediction tools to improve outcomes in early HR+/HER2– breast cancer
por: Curigliano, Giuseppe, et al.
Publicado: (2023)

Interaction of letrozole and its degradation products with aromatase: chemometric assessment of kinetics and structure-based binding validation
por: De Luca, Michele, et al.
Publicado: (2022)

Soluble Biomarkers with Prognostic and Predictive Value in Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy
por: Honrubia-Peris, Beatriz, et al.
Publicado: (2021)

Effect of aromatase inhibitor letrozole on the proliferation of spermatogonia by regulating the MAPK pathway
por: Wang, Shunde, et al.
Publicado: (2018)

Predictive and prognostic impact of tumour-infiltrating lymphocytes in triple-negative breast cancer treated with neoadjuvant chemotherapy
por: Herrero-Vicent, Carmen, et al.
Publicado: (2017)

Differences between the non-steroidal aromatase inhibitors anastrozole and letrozole – of clinical importance?
por: Geisler, J
Publicado: (2011)

A prognostic index for locoregional recurrence after neoadjuvant chemotherapy
por: Herrero-Vicent, C, et al.
Publicado: (2016)

The Value of Case Reports in Systematic Reviews from Rare Diseases. The Example of Enzyme Replacement Therapy (ERT) in Patients with Mucopolysaccharidosis Type II (MPS-II)
por: Sampayo-Cordero, Miguel, et al.
Publicado: (2020)

The Impact of Excluding Nonrandomized Studies From Systematic Reviews in Rare Diseases: “The Example of Meta-Analyses Evaluating the Efficacy and Safety of Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis”
por: Sampayo-Cordero, Miguel, et al.
Publicado: (2021)

Nobody dares stopping clinical research, not even COVID-19
por: Malfettone, Andrea, et al.
Publicado: (2021)

Serum Phospholipids Fatty Acids and Breast Cancer Risk by Pathological Subtype
por: Lope, Virginia, et al.
Publicado: (2020)

Intimal Sarcoma with MDM2/CDK4 Amplification and p16 Overexpression: A Review of Histological Features in Primary Tumor and Xenograft, with Immunophenotype and Molecular Profiling
por: Giner, Francisco, et al.
Publicado: (2023)

A Polymorphism at the 3′-UTR Region of the Aromatase Gene Is Associated with the Efficacy of the Aromatase Inhibitor, Anastrozole, in Metastatic Breast Carcinoma
por: Liu, Lei, et al.
Publicado: (2013)

Nanocapillarity and Liquid Bridge-Mediated Force between Colloidal Nanoparticles
por: MacDowell, Luis G., et al.
Publicado: (2018)

Early operable breast cancer in elderly women treated with an aromatase inhibitor letrozole as sole therapy
por: Balakrishnan, A, et al.
Publicado: (2011)

Letrozole, an aromatase inhibitor, improves seminal parameters and hormonal profile in aged endangered Markhoz bucks
por: Rezaei, Ako, et al.
Publicado: (2022)

Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study
por: Ellis, Matthew J., et al.
Publicado: (2015)

An integrated analysis of miRNA and gene copy numbers in xenografts of Ewing's sarcoma
por: Mosakhani, Neda, et al.
Publicado: (2012)

Early Imaging and Molecular Changes with Neoadjuvant Bevacizumab in Stage II/III Breast Cancer
por: López-Vega, José Manuel, et al.
Publicado: (2021)

Intratumoral concentration of estrogens and clinicopathological changes in ductal carcinoma in situ following aromatase inhibitor letrozole treatment
por: Takagi, K, et al.
Publicado: (2013)

CDK4/6 Inhibitors in Hormone Receptor-Positive Metastatic Breast Cancer: Current Practice and Knowledge
por: de Melo Gagliato, Debora, et al.
Publicado: (2020)

Impact of SARS-CoV-2 Infection on Patients with Cancer: Retrospective and Transversal Studies in Spanish Population
por: Garde-Noguera, Javier, et al.
Publicado: (2020)

The PI3K inhibitor taselisib overcomes letrozole resistance in a breast cancer model expressing aromatase
por: Hoeflich, Klaus P., et al.
Publicado: (2016)

Evaluation of Different Doses of the Aromatase Inhibitor Letrozole for the Treatment of Ectopic Pregnancy and Its Effect on Villous Trophoblastic Tissue
por: Alabiad, Mohamed Ali, et al.
Publicado: (2022)

Campomanes : economista y político de Carlos III /
por: Llombart, Vicent
Publicado: (1992)

Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial
por: Gavilá, Joaquín, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_kr3la0ivhr3ns02uti9cll69ga